Advertisement

Topics

The Common Pharmaceutical Market of the Eurasian Economic Union: A Regulatory Review.

08:00 EDT 1st November 2017 | BioPortfolio

Summary of "The Common Pharmaceutical Market of the Eurasian Economic Union: A Regulatory Review."

According to the Treaty on the Eurasian Economic Union, a common pharmaceutical market was supposed to become operational on January 1, 2016. Nevertheless, the responsible parties did not meet the deadline. Although a majority of the draft guidelines regulating this process were already known in 2014 and 2015, the anticipated process itself caused anxiety among representatives of the foreign pharma industry, who tried to prepare for coming challenges. Among other possible issues, the ambiguity of transitional periods and a lack of approved legislation were noted. Now only a few months remain until the end of 2016, but the market is still not functional. Furthermore, key documents relevant to the market still require approval by the Eurasian Economic Commission, and some of them even require discussion by representatives of member states. The present review provides readers with basic knowledge about regulatory procedures within the EAEU and the document approval process. It analyzes essential legislative acts and consequences for the pharma industry to take into account, including marketing authorization pathways, specific dossier requirements, and dates of their implementation. At the same time, reasons for the delay in the market's opening and future perspectives are discussed.

Affiliation

Journal Details

This article was published in the following journal.

Name: Therapeutic innovation & regulatory science
ISSN: 2168-4804
Pages: 751-755

Links

DeepDyve research library

PubMed Articles [19086 Associated PubMed Articles listed on BioPortfolio]

Pharmaceutical markets regulation overview of the selected European Union countries.

Introduction: Pharmacy markets, operating in the European Union are regulated by national laws. In many of them, the main restrictions concern the process of creating a new pharmacy - institutions. Th...

Renovations Needed: the FDA's Floor/Ceiling Framework, Preemption, and the Opioid Epidemic.

The FDA's regulatory framework for pharmaceuticals uses a "floor/ceiling" model: administrative rules set a "floor" of minimum safety, while state tort liability sets a "ceiling" of maximum protection...

Preclinical therapies to prevent or treat fracture non-union: A systematic review.

Non-union affects up to 10% of fractures and is associated with substantial morbidity. There is currently no single effective therapy for the treatment or prevention of non-union. Potential treatments...

The Drug Shortage Crisis in the United States: Impact on Cancer Pharmaceutical Safety.

Drug shortages pose a significant public health concern in the United States, and cancer drugs are among those most affected. Shortages present serious safety risks for patients and substantial burden...

A systematic review of the stability of finished pharmaceutical products and drug substances beyond their labeled expiry dates.

In recent years, there has been a very active debate about the stability of drug products especially after exceeding the expiry dates. The regulatory authorities require comprehensive stability data f...

Clinical Trials [3665 Associated Clinical Trials listed on BioPortfolio]

Post Market Clinical Follow-Up Study Protocol for PROCOTYL® C Acetabular Components

MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in th...

PMCF Study Protocol for PROFEMUR® Gladiator Plasma Femoral Stems and PROCOTYL® L Beaded Acetabular Components

MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in th...

PMCF Study for PROFEMUR® Am Femoral Components and PROCOTYL® O HA Coated Acetabular Components

MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) and resurfacing component...

A Prospective Randomized Controlled Trial on the Use of Bone Morphogenetic 7 (BMP-7) (OP-1®) and Demineralized Bone Matrix in Tibial Non-Union

The researchers propose a prospective, randomised partially-blinded study to investigate the clinical and radiological outcome, effect on quality of life and socio-economic impact of non-u...

Zenith® TXD Post-market Surveillance in Japan

The study is a post-market surveillance study required by Japanese Regulatory Authorities as a condition of approval

Medical and Biotech [MESH] Definitions

The collective designation of three organizations with common membership: the European Economic Community (Common Market), the European Coal and Steel Community, and the European Atomic Energy Community (Euratom). It was known as the European Community until 1994. It is primarily an economic union with the principal objectives of free movement of goods, capital, and labor. Professional services, social, medical and paramedical, are subsumed under labor. The constituent countries are Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Portugal, Spain, Sweden, and the United Kingdom. (The World Almanac and Book of Facts 1997, p842)

Economic aspects of the fields of pharmacy and pharmacology as they apply to the development and study of medical economics in rational drug therapy and the impact of pharmaceuticals on the cost of medical care. Pharmaceutical economics also includes the economic considerations of the pharmaceutical care delivery system and in drug prescribing, particularly of cost-benefit values. (From J Res Pharm Econ 1989;1(1); PharmacoEcon 1992;1(1))

Review of the medical necessity of hospital or other health facility admissions, upon or within a short time following an admission, and periodic review of services provided during the course of treatment.

An economic union of Azerbaijan, Armenia, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Uzbekistan and Ukraine.

A political and economic system characterized by individual rights, by private or corporate ownership of capital goods, and by prices, production, and the distribution of goods that are determined mainly by competition in a free market. (From Merriam-Webster's Collegiate Dictionary, 10th ed)

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Relevant Topic

Anxiety Disorders
Anxiety is caused by stress. It is a natural reaction, and is beneficial in helping us deal with tense situations and pressure. It is deterimental when is becomes an excessive, irrational dread of everyday situations. The most common types of anxiety di...


Searches Linking to this Article